Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
741 to 760 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Review of Immune Checkpoint Blockade for the General Surgeon. | J Surg Res | 2023 | 36228339 | PubTator, text mining | PubMed |
| Pescadillo ribosomal biogenesis factor 1 reduction suppresses tumour growth and renders chemosensitivity of head and neck squamous cell carcinoma. | Cancer Med | 2023 | 36217758 | PubTator, text mining | PubMed |
| MTAP deficiency contributes to immune landscape remodelling and tumour evasion. | Immunology | 2023 | 36183155 | PubTator, text mining | PubMed |
| Dendritic cell-mimicking scaffolds for ex vivo T cell expansion. | Bioact Mater | 2023 | 36157246 | PubTator, text mining | PubMed |
| GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells. | Cell Mol Gastroenterol Hepatol | 2023 | 36155259 | PubTator, text mining | PubMed |
| Identification of senescence-related molecular subtypes and key genes for prostate cancer. | Asian J Androl | 2023 | 36124532 | PubTator, text mining | PubMed |
| Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma. | Clin Cancer Res | 2023 | 36112545 | PubTator, text mining | PubMed |
| COL3A1: Potential prognostic predictor for head and neck cancer based on immune-microenvironment alternative splicing. | Cancer Med | 2023 | 36039012 | PubTator, text mining | PubMed |
| Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy. | Haematologica | 2023 | 35950534 | PubTator, text mining | PubMed |
| Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic stem cell tranplantation is predictive of subsequent relapse and survival. | Haematologica | 2023 | 35924575 | PubTator, text mining | PubMed |
| Cancer vaccine strategies using self-replicating RNA viral platforms. | Cancer Gene Ther | 2023 | 35821284 | PubTator, text mining | PubMed |
| Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients. | Cancer Med | 2023 | 35621244 | PubTator, text mining | PubMed |
| Self-replicating vehicles based on negative strand RNA viruses. | Cancer Gene Ther | 2023 | 35169298 | PubTator, text mining | PubMed |
| Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing. | Bioengineered | 2022 | 37105769 | PubTator, text mining | PubMed |
| Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer. | J Immunother Cancer | 2022 | 36939214 | PubTator, text mining | PubMed |
| Emerging role of hypoxia-inducible factor-1α in inflammatory autoimmune diseases: A comprehensive review. | Front Immunol | 2022 | 36761171 | PubTator, text mining | PubMed |
| Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. | Front Immunol | 2022 | 36741391 | PubTator, text mining | PubMed |
| Identification and classification of distinct surface markers of T regulatory cells. | Front Immunol | 2022 | 36741366 | PubTator, text mining | PubMed |
| Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. | Front Oncol | 2022 | 36713553 | PubTator, text mining | PubMed |
| Inhibition of galectins in cancer: Biological challenges for their clinical application. | Front Immunol | 2022 | 36703969 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=38